PFE PFIZER INC

NYSE pfizer.com


$ 25.13 $ -0.73 (-2.83 %)    

Friday, 14-Nov-2025 15:52:36 EST
QQQ $ 608.53 $ 0.46 (0.08 %)
DIA $ 471.77 $ -2.94 (-0.62 %)
SPY $ 671.64 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.87 $ -6.91 (-1.8 %)
$ 25.06
$ 25.69
$ 25.13 x 3,921
$ 25.14 x 8,738
$ 24.97 - $ 25.76
$ 19.83 - $ 27.21
96,241,626
na
142.48B
$ 0.49
$ 14.50
TBD
na
na ($ 0.07)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-28-2025 10-Q
2 08-05-2025 06-29-2025 10-Q
3 05-05-2025 03-30-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-04-2024 09-29-2024 10-Q
6 08-05-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-08-2023 10-01-2023 10-Q
10 08-09-2023 07-02-2023 10-Q
11 05-10-2023 04-02-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-09-2022 10-02-2022 10-Q
14 08-10-2022 07-03-2022 10-Q
15 05-11-2022 04-03-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-12-2021 10-03-2021 10-Q
18 08-12-2021 07-04-2021 10-Q
19 05-13-2021 04-04-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-27-2020 10-Q
22 08-06-2020 06-28-2020 10-Q
23 05-07-2020 03-29-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-07-2019 09-29-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 07-01-2018 10-Q
31 05-10-2018 04-01-2018 10-Q
32 02-22-2018 12-31-2017 10-K
33 11-09-2017 10-01-2017 10-Q
34 08-10-2017 07-02-2017 10-Q
35 05-11-2017 04-02-2017 10-Q
36 02-23-2017 12-31-2016 10-K
37 11-10-2016 10-02-2016 10-Q
38 08-11-2016 07-03-2016 10-Q
39 05-12-2016 04-03-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 deal-dispatch-warner-bros-billcom-c3-aikey-auctions-and-buyouts-shake-the-market

Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com...

 fear-of-an-ai-bubble-this-sector-is-quietly-surging-while-tech-sinks

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

 ozempic-maker-novo-nordisk-faces-board-shakeup

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesi...

Core News & Articles

-SEC Filing-SEC Filing

Core News & Articles

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscapeCom...

 pfizer-seeks-to-exit-biontech-investment-after-lucrative-covid-vaccine-run

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine part...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-11-13/pfizer-looks-to-sell-stake-in-pandemic-vaccine-partner-biontech

 novo-nordisks-100-million-coramitug-shows-promise-in-reducing-heart-failure-biomarker

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Pha...

 novo-nordisk-rises-despite-metsera-loss-slashes-wegovy-price-in-india

Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.

 cogent-biosciences-lead-cancer-drug-cuts-disease-progression-or-death-risk-by-50-in-stomach-cancer-trial

Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIS...

 pfizer-clinches-10-billion-deal-to-buy-obesity-drug-maker-metsera-outbidding-novo-nordisk-in-fierce-battle-for-weight-loss-market-dominance

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying build...

 eli-lilly-novo-nordisk-make-weight-loss-drugs-more-affordable-via-medicare-medicaid-trumprx

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION